What question did this study set out to answer?

This study aims to assess the barriers and challenges healthcare providers face in accessing and getting approval for PCSK9 inhibitor prescriptions.

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association

View Full Paper

Ask AI

Bookmark

Authors

Healthcare provider survey reveals documentation and approval issues for PCSK9 inhibitors in high-risk patients, suggesting improvements are needed.

This study aims to assess the barriers and challenges healthcare providers face in accessing and getting approval for PCSK9 inhibitor prescriptions.
Conducted an online survey by the National Lipid Association in 2016.
Surveyed 434 healthcare workers experienced in treating lipid disorders and high-risk patients with ASCVD or familial hypercholesterolemia.
Analyzed barriers related to documentation and insurer processes for approving PCSK9 inhibitors.
71.3% of providers consider PCSK9 inhibitors for statin-intolerant patients.
Over 85% of initial prescription requests are denied, primarily due to documentation issues.
Provider approval rates are significantly higher for familial hypercholesterolemia patients (43%) compared to ASCVD patients (36%).

Cohen et al. (2017) studied this question.

View Full Paper

Ask AI

Bookmark

Healthcare provider survey reveals documentation and approval issues for PCSK9 inhibitors in high-risk patients, suggesting improvements are needed.